SG11201804510PA - Biparatopic polypeptides antagonizing wnt signaling in tumor cells - Google Patents
Biparatopic polypeptides antagonizing wnt signaling in tumor cellsInfo
- Publication number
- SG11201804510PA SG11201804510PA SG11201804510PA SG11201804510PA SG11201804510PA SG 11201804510P A SG11201804510P A SG 11201804510PA SG 11201804510P A SG11201804510P A SG 11201804510PA SG 11201804510P A SG11201804510P A SG 11201804510PA SG 11201804510P A SG11201804510P A SG 11201804510PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ablynx
- rhein
- biparatopic
- boehringer ingelheim
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000013814 Wnt Human genes 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title abstract 2
- 230000011664 signaling Effects 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 abstract 2
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004156 Wnt signaling pathway Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/093478 Al WIPO I PCT (43) International Publication Date 8 June 2017 (08.06.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.170) Published: with international search report (Art 21(3)) with sequence listing part of description (Rule 5.2(a)) (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) C07K 16/18 (2006.01) (21) International Application Number: PCT/EP2016/079575 (22) International Filing Date: 2 December 2016 (02.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15197999.4 4 December 2015 (04.12.2015) EP (71) Applicant: BOEHRINGER INGELHEIM INTERNA- TIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 In- gelheim Am Rhein (DE). (72) Inventors: ZINZALLA, Vittoria; Boehringer Ingelheim GmbH/ Corporate Patents, Binger Strasse 173, 55216 In- gelheim Am Rhein (DE). KUENKELE, Klaus-Peter; Boehringer Ingelheim GmbH/ Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). BUYSE, Marie-Ange; Ablynx N.V. Technologiepark 21, 9052 Zwijnaarde (BE). CROMIE, Karen; ABLYNX N.V Tech- nologiepark 21, 9052 Zwijnaarde (BE). STAELENS, Stephanie; Ablynx N.V. Technologiepark 21, 9052 Zwijn- aarde (BE). STRUBBE, Beatrijs; Ablynx N.V. Technolo- giepark 21, 9052 Zwijnaarde (BE). (74) Agents: SIMON, Elke et al.; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 In- gelheim Am Rhein (DE). W O 20 17 /093 47 8 Al (54) Title: BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS (57) : The invention provides novel biparatopic LRPS/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRPS/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197999 | 2015-12-04 | ||
| PCT/EP2016/079575 WO2017093478A1 (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804510PA true SG11201804510PA (en) | 2018-06-28 |
Family
ID=54782606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804510PA SG11201804510PA (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10597449B2 (en) |
| EP (2) | EP3797790A1 (en) |
| JP (2) | JP6728355B2 (en) |
| KR (1) | KR102802241B1 (en) |
| CN (1) | CN108289943B (en) |
| AR (1) | AR106949A1 (en) |
| AU (1) | AU2016363787B2 (en) |
| BR (1) | BR112018010537A2 (en) |
| CA (1) | CA3006235A1 (en) |
| CL (1) | CL2018001384A1 (en) |
| CO (1) | CO2018005680A2 (en) |
| CY (1) | CY1123454T1 (en) |
| DK (1) | DK3383425T3 (en) |
| EA (1) | EA201891331A1 (en) |
| ES (1) | ES2821099T3 (en) |
| HR (1) | HRP20201528T1 (en) |
| HU (1) | HUE051777T2 (en) |
| IL (1) | IL259119B (en) |
| LT (1) | LT3383425T (en) |
| MA (2) | MA43368B1 (en) |
| MX (1) | MX380414B (en) |
| MY (1) | MY200933A (en) |
| NZ (1) | NZ742037A (en) |
| PE (1) | PE20181515A1 (en) |
| PH (1) | PH12018501155B1 (en) |
| PL (1) | PL3383425T3 (en) |
| PT (1) | PT3383425T (en) |
| RS (1) | RS60823B1 (en) |
| SA (1) | SA518391728B1 (en) |
| SG (1) | SG11201804510PA (en) |
| SI (1) | SI3383425T1 (en) |
| TW (1) | TWI734719B (en) |
| UA (1) | UA122079C2 (en) |
| WO (1) | WO2017093478A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013130364A1 (en) | 2012-02-28 | 2013-09-06 | Novartis Ag | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
| UA121914C2 (en) | 2015-11-18 | 2020-08-10 | Мерк Шарп І Доум Корп. | Pd1 and/or lag3 binders |
| SI3383425T1 (en) * | 2015-12-04 | 2020-11-30 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| WO2018220080A1 (en) * | 2017-05-31 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing wnt signaling in tumor cells |
| US20200368285A1 (en) | 2017-08-07 | 2020-11-26 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CA3083969A1 (en) | 2017-11-29 | 2019-06-06 | Board Of Regents Of The University Of Texas System | Compositions and methods for cancer therapy |
| WO2019126398A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
| CA3104526A1 (en) * | 2018-07-05 | 2020-01-09 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| WO2020200998A1 (en) | 2019-03-29 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| EP3947455A1 (en) * | 2019-03-29 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
| CN114040926B (en) | 2019-05-04 | 2025-07-29 | 印希比生物科学有限公司 | Polypeptide binding to CD123 and uses thereof |
| EP3966338A1 (en) * | 2019-05-08 | 2022-03-16 | Inhibrx, Inc. | Cd123 targeted immunotherapies |
| JP2022544307A (en) * | 2019-08-14 | 2022-10-17 | モッドマブ セラピューティクス インコーポレイテッド | Antibodies that bind to LRP6 protein and methods of use |
| JP2022544308A (en) * | 2019-08-14 | 2022-10-17 | モッドマブ セラピューティクス インコーポレイテッド | Antibodies that bind to LRP5 protein and methods of use |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| CN112794914B (en) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | ALK nano antibody developed based on phage display technology and application thereof |
| WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| EP4314075A4 (en) * | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANTS OF NUCLEIC ACID LIBRARIES FOR CD3 |
| WO2023286854A1 (en) * | 2021-07-16 | 2023-01-19 | ブライトパス・バイオ株式会社 | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| IL321903A (en) * | 2023-01-05 | 2025-09-01 | Harpoon Therapeutics Inc | Trop2 targeting trispecific protein for treatment of cancer |
| CN116375851B (en) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | A kind of nanobody against avian influenza virus NP protein and its preparation method and application |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE452975T1 (en) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | IMMUNOGLOBULINS WITHOUT LIGHT CHAINS |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| JP2003530838A (en) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | Albumin fusion protein |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BRPI0316092B8 (en) | 2002-11-08 | 2021-05-25 | Ablynx Nv | single domain antibodies directed against tumor necrosis factor alpha and uses for them |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| RU2464276C2 (en) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Improved nanobodies against tumour necrosis factor-alpha |
| US7622267B2 (en) * | 2006-05-30 | 2009-11-24 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods |
| EP2447558B1 (en) | 2006-06-08 | 2013-05-29 | NSK Ltd. | Method for manufacturing a drawn cup needle roller bearing having a seal ring |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN100428934C (en) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | Application of cumarin kind compound in preparation of medicine for inducing nerve stem cell orienting differentiation |
| JP2010502208A (en) | 2006-09-08 | 2010-01-28 | アブリンクス エン．ヴェー． | Serum albumin binding protein with long half-life |
| WO2008068280A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2009056634A2 (en) | 2007-11-02 | 2009-05-07 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| DE112009000507T5 (en) | 2008-03-05 | 2011-02-10 | Ablynx Nv | Novel antigen-binding dimer complexes, process for their preparation and their use |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
| US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
| WO2011075861A1 (en) | 2009-12-23 | 2011-06-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| AU2011212442A1 (en) | 2010-02-05 | 2012-08-09 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| AU2011222980B2 (en) | 2010-03-03 | 2016-08-11 | Ablynx N.V. | Biparatopic Abeta binding polypeptides |
| US8846041B2 (en) * | 2010-03-24 | 2014-09-30 | Genentech, Inc. | Anti-LRP6 antibodies |
| US9290573B2 (en) * | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| EP3345926B1 (en) | 2010-05-06 | 2023-04-05 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| SG189271A1 (en) * | 2010-10-20 | 2013-05-31 | Genentech Inc | Methods and compositions for modulating the wnt pathway |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| PH12022550313A1 (en) | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR102143506B1 (en) | 2011-08-17 | 2020-08-12 | 글락소 그룹 리미티드 | Modified proteins and peptides |
| JP2015502741A (en) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | Low density lipoprotein related protein 6 (LRP6)-half-life extended construct |
| JP5949270B2 (en) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | Audio decoding apparatus, audio decoding method, and audio decoding computer program |
| EP2888279A1 (en) * | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
| SI3383425T1 (en) | 2015-12-04 | 2020-11-30 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
-
2016
- 2016-12-02 SI SI201630953T patent/SI3383425T1/en unknown
- 2016-12-02 ES ES16808971T patent/ES2821099T3/en active Active
- 2016-12-02 MA MA43368A patent/MA43368B1/en unknown
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/en active
- 2016-12-02 RS RS20201124A patent/RS60823B1/en unknown
- 2016-12-02 NZ NZ742037A patent/NZ742037A/en unknown
- 2016-12-02 AR ARP160103720A patent/AR106949A1/en unknown
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 PH PH1/2018/501155A patent/PH12018501155B1/en unknown
- 2016-12-02 MA MA054648A patent/MA54648A/en unknown
- 2016-12-02 MX MX2018006760A patent/MX380414B/en unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/en unknown
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en not_active Ceased
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/en unknown
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 CA CA3006235A patent/CA3006235A1/en active Pending
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/en active Search and Examination
- 2016-12-02 EA EA201891331A patent/EA201891331A1/en unknown
- 2016-12-02 PT PT168089712T patent/PT3383425T/en unknown
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/en unknown
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/en unknown
- 2016-12-02 KR KR1020187019053A patent/KR102802241B1/en active Active
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/en active Active
- 2016-12-02 UA UAA201807120A patent/UA122079C2/en unknown
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/en active Active
- 2016-12-02 TW TW105139826A patent/TWI734719B/en active
- 2016-12-02 HR HRP20201528TT patent/HRP20201528T1/en unknown
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
-
2018
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/en unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/en unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/en unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/en not_active Withdrawn
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |